Mutual of America Capital Management LLC Has $2.41 Million Stock Position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

Mutual of America Capital Management LLC cut its position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 17.9% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 62,342 shares of the specialty pharmaceutical company’s stock after selling 13,586 shares during the period. Mutual of America Capital Management LLC owned 0.19% of Collegium Pharmaceutical worth $2,409,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Russell Investments Group Ltd. grew its stake in Collegium Pharmaceutical by 3.2% in the first quarter. Russell Investments Group Ltd. now owns 33,084 shares of the specialty pharmaceutical company’s stock valued at $1,284,000 after acquiring an additional 1,011 shares during the period. State Board of Administration of Florida Retirement System increased its stake in Collegium Pharmaceutical by 55.8% during the 1st quarter. State Board of Administration of Florida Retirement System now owns 15,410 shares of the specialty pharmaceutical company’s stock valued at $598,000 after purchasing an additional 5,520 shares in the last quarter. Vanguard Group Inc. raised its holdings in Collegium Pharmaceutical by 0.8% during the first quarter. Vanguard Group Inc. now owns 2,330,728 shares of the specialty pharmaceutical company’s stock worth $90,479,000 after buying an additional 17,942 shares during the last quarter. CANADA LIFE ASSURANCE Co lifted its stake in shares of Collegium Pharmaceutical by 17.5% in the first quarter. CANADA LIFE ASSURANCE Co now owns 31,852 shares of the specialty pharmaceutical company’s stock valued at $1,235,000 after buying an additional 4,742 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD grew its holdings in shares of Collegium Pharmaceutical by 1.9% during the first quarter. Price T Rowe Associates Inc. MD now owns 29,282 shares of the specialty pharmaceutical company’s stock valued at $1,137,000 after buying an additional 535 shares during the last quarter.

Collegium Pharmaceutical Trading Down 1.5 %

Shares of COLL stock opened at $29.96 on Friday. The company has a quick ratio of 0.88, a current ratio of 0.97 and a debt-to-equity ratio of 3.43. The firm has a market cap of $966.21 million, a P/E ratio of 12.91 and a beta of 0.95. The company has a 50 day moving average of $35.69 and a 200-day moving average of $34.77. Collegium Pharmaceutical, Inc. has a 12-month low of $25.16 and a 12-month high of $42.29.

Wall Street Analysts Forecast Growth

COLL has been the topic of several recent research reports. Piper Sandler reaffirmed a “neutral” rating and issued a $37.00 price target on shares of Collegium Pharmaceutical in a research report on Friday, October 11th. Truist Financial raised their price objective on Collegium Pharmaceutical from $40.00 to $42.00 and gave the company a “buy” rating in a research note on Friday, August 9th. Needham & Company LLC reiterated a “hold” rating on shares of Collegium Pharmaceutical in a research note on Friday, August 9th. StockNews.com lowered shares of Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, October 23rd. Finally, HC Wainwright upped their price objective on shares of Collegium Pharmaceutical from $47.00 to $50.00 and gave the stock a “buy” rating in a research report on Thursday, September 5th. Two analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $42.60.

Insider Activity

In other news, EVP Thomas B. Smith sold 9,593 shares of the firm’s stock in a transaction on Friday, September 13th. The stock was sold at an average price of $36.62, for a total value of $351,295.66. Following the completion of the transaction, the executive vice president now directly owns 53,816 shares of the company’s stock, valued at $1,970,741.92. This trade represents a 15.13 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Shirley R. Kuhlmann sold 19,248 shares of the business’s stock in a transaction on Thursday, September 5th. The shares were sold at an average price of $38.30, for a total value of $737,198.40. Following the sale, the executive vice president now owns 120,161 shares in the company, valued at approximately $4,602,166.30. The trade was a 13.81 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 3.98% of the company’s stock.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.